A Phase 3 interventional study of bevacizumab [Avastin] and cisplatin in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 91 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-22.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 28th largest by enrollment of the 198 interventional ones that give a count, is one of 22 that started in 2009, is one of 46 in phase 3, and was the 115th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
Hunan Province Tumor Hospital · Sites in China
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 132 · Phase 3 47 · Phase 4 3
First in 1994; this study’s year is marked. 22 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 376 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 198 interventional studies. Of the 159 that completed or were terminated, 62 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 213 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 16 under way, 8 of them phase 3. Of 161 finished, 96 (60%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 38th largest by enrollment of the 142 interventional ones that give a count, is one of 11 that started in 2009, is one of 48 in phase 3, and was the 37th registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
4 of the studies testing cisplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer. In Part 1, patients will receive 4 cycles of treatment with Avastin (7.5mg/kg iv) plus cisplatin (75mg/m2 iv) plus pemetrexed (500mg/m2 iv) on day 1 of each 3-week cycle. In Part 2, patients responding to treatment will be randomized to receive further treatment cycles of Avastin (7.5mg/kg iv every 3 weeks) with or without pemetrexed (500mg/m2 iv every 3 weeks). Anticipated time on study treatment is until disease progression. Target sample size is \<500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: cisplatin · Drug: pemetrexed
Drug: bevacizumab [Avastin]
Drug: bevacizumab [Avastin] · Drug: pemetrexed
7.5mg/kg iv on day 1 of each 3-week cycle
75mg/m2 iv on day 1 of each 3-week cycle
500mg/m2 iv on day 1 of each 3-week cycle
Progression Free Survival During Maintenance Treatment Phase
Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Overall Survival During Maintenance Treatment Phase
Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Best Overall Response Rate During Maintenance Treatment Phase
The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Duration of Response During Maintenance Treatment Phase
Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Duration of Disease Control During Maintenance Treatment Phase
Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
Time frame: Up to 21 months
Incidence of Adverse Events and Serious Adverse Event
An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.
Time frame: Up to 21 months
Number of Participants With Marked Laboratory Abnormalities
Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ).
Time frame: Up to 21 months
Quality of Life
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.
Time frame: Up to 21 months
A total of 414 participants were screened out of which 38 participants were excluded for not meeting the eligibility criteria, declining to participate, or for other reasons. A total of 376 participants were recruited over an 18-month period across 81 centers in 11 countries from 17 August 2009 to 3 May 2011.
| Milestone | Induction Treatment Phase | Bevacizumab Maintenance Treatment (Trt) Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|---|
| Started | 376 | 0 | 0 |
| Completed | 253 | 0 | 0 |
| Not completed | 123 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 0 | 0 |
| Withdrew: Death | 77 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Didn't meet maintenance phase criteria | 27 | 0 | 0 |
| Withdrew: Other reason | 5 | 0 | 0 |
| Milestone | Induction Treatment Phase | Bevacizumab Maintenance Treatment (Trt) Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|---|
| Started | 0 | 125 | 128 |
| Completed | 0 | 77 | 83 |
| Not completed | 0 | 48 | 45 |
| Withdrew: Death | 0 | 42 | 34 |
| Withdrew: Investigators decision | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 8 |
| Withdrew: Other reason | 0 | 1 | 3 |
Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
| Months | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| Progression Free Survival During Maintenance Treatment Phase | 6.6 (6.0 to 7.8) | 10.2 (9.1 to 11.7) |
Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
| Months | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| Overall Survival During Maintenance Treatment Phase | 15.7 (14.3 to NA) | NA (NA to NA) |
The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
| percentage of participants | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| Partial response (PR) | 50 (40.9 to 59.1) | 55.5 (46.4 to 64.3) |
| Stable disease (SD) | 50 (40.9 to 59.1) | 44.5 (35.7 to 53.6) |
Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
| Months | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| Duration of Response During Maintenance Treatment Phase | 5.7 (4.9 to 7.2) | 9.2 (6.8 to 10.4) |
Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.
| Months | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| Duration of Disease Control During Maintenance Treatment Phase | 4.9 (3.9 to 5.7) | 7.8 (6.8 to 9.7) |
An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.
| Participants | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B | No Maintenance Trt |
|---|---|---|---|
| AE | 116 | 123 | 119 |
| SAE | 26 | 42 | 70 |
Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\^9/L), for Lymphocytes was 0.70-7.60 (10\^9/L), and Neutrophil 1.50-9.25 (10\^9/L ).
| Participants | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B | No Maintenance Trt |
|---|---|---|---|
| Alanine amino transferase (ALT) | 18 | 26 | 8 |
| Aspartate amino transferase (AST) | 18 | 26 | 8 |
| Alkaline phosphatase | 18 | 26 | 8 |
| Hemoglobin | 28 | 30 | 25 |
| International normalized ratio (INR) | 1 | 0 | 0 |
| Lymphocytes | 28 | 30 | 25 |
| Neutrophils | 28 | 30 | 25 |
| Platelets | 28 | 30 | 25 |
| Serum creatinine | 18 | 26 | 8 |
| WBC | 28 | 30 | 25 |
| Activated partial thromboplastin time (aPTT) | 1 | 0 | 0 |
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \[EORTC QLQ-LC13\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.
| Score on scale | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B |
|---|---|---|
| [Pre-ind BL] Global Health Status Scale n=116,121 | 57.9 ± 23.90 | 59.7 ± 21.74 |
| [Pre-ind BL] Physical Functional Scale (n=118,121) | 74.8 ± 23.69 | 79.4 ± 18.09 |
| [Pre-ind BL] Role Functional Scale (n=118,121) | 68.4 ± 32.50 | 71.1 ± 28.28 |
| [Pre-ind BL] Emotional Functional Scale n=117,121 | 71.7 ± 21.93 | 69.8 ± 21.97 |
| [Pre-ind BL] Cognitive Functional Scale n=117,121 | 86.0 ± 21.55 | 88.0 ± 16.70 |
| [Pre-ind BL]] Social Functional Scale (n=116,120) | 79.3 ± 25.60 | 78.7 ± 26.10 |
| [Pre-ind BL] Fatigue Symptom Scale (n=118,121) | 33.3 ± 27.18 | 31.5 ± 21.73 |
| [Pre-ind BL] Nausea & Vomiting Scale n=118,121 | 7.2 ± 17.50 | 4.3 ± 12.46 |
| [Pre-ind BL] Pain Symptom Scale (n=118,121) | 36.7 ± 31.92 | 24.7 ± 26.88 |
| [Pre-ind BL] Dyspnea Symptom Scale (n=118,121) | 29.7 ± 30.75 | 30.6 ± 29.69 |
| [Pre-ind BL] Insomnia Symptom Scale n=118,121 | 33.3 ± 34.59 | 33.9 ± 30.42 |
| [Pre-ind BL] Appetite Loss Symptom Scale n=118,121 | 19.2 ± 30.01 | 18.7 ± 29.15 |
| [Pre-ind BL]] Constipation Symptom Scale n=118,121 | 18.6 ± 30.68 | 9.1 ± 20.18 |
| [Pre-ind BL] Diarrhea Symptom Scale (n=117,121) | 7.1 ± 17.96 | 5.2 ± 14.91 |
| [Pre-ind BL]Financial Difficulties Scale n=114,120 | 17.3 ± 30.48 | 17.2 ± 29.62 |
| [MTC Cycle 3]Global Health Status (n=69,87) | 63.3 ± 20.02 | 58.6 ± 19.71 |
| [MTC Cycle 3]Physical Functional Scale (n=69,87) | 77.1 ± 20.72 | 76.0 ± 20.37 |
| [MTC Cycle 3]Role Functional Scale (n=69,87) | 74.2 ± 27.79 | 69.9 ± 28.51 |
| [MTC Cycle 3]Emotional Functional Scale (n=69,87) | 82.5 ± 19.86 | 78.4 ± 18.48 |
| [MTC Cycle 3]Cognitive Functional Scale (n=69,87) | 84.3 ± 23.20 | 82.6 ± 19.17 |
| [MTC Cycle 3]Social Functional Scale (n=69,87) | 82.1 ± 25.62 | 73.0 ± 24.28 |
| [MTC Cycle 3]Fatigue Symptom Scale (n=69,87) | 32.1 ± 22.88 | 34.5 ± 21.50 |
| [MTC Cycle 3]Nausea and Vomiting Scale (n=69,87) | 7.2 ± 16.78 | 8.8 ± 12.92 |
| [MTC Cycle 3]Pain Symptom Scale (n=69,87) | 23.9 ± 27.64 | 17.4 ± 21.85 |
| [MTC Cycle 3]Dyspnea Symptom Scale (n=69,87) | 26.1 ± 27.93 | 29.9 ± 26.91 |
| MTC Cycle 3]Appetite Loss Symptom Scale (n=69,87) | 13.5 ± 22.37 | 18.4 ± 25.80 |
| [MTC Cycle 3]Insomnia Symptom Scale (n=69,87) | 19.3 ± 24.53 | 19.5 ± 25.19 |
| [MTC Cycle 3]Constipation Symptom Scale (n=69,87) | 10.1 ± 19.22 | 11.1 ± 20.12 |
| [MTC Cycle 3]Diarrhea Symptom Scale (n=69,87) | 3.4 ± 12.97 | 5.7 ± 14.56 |
| [MTC Cycle 3]Financial Difficulties Scale (n=68,86 | 18.1 ± 27.88 | 19.4 ± 26.30 |
| [MTC Cycle 5] Global Health Status (n=51,77) | 63.2 ± 20.36 | 62.9 ± 18.81 |
| [MTC Cycle 5] Physical Functional Scale (n=51,77) | 78.7 ± 21.29 | 78.4 ± 15.45 |
| [MTC Cycle 5] Role Functional Scale (n=51,77) | 74.5 ± 31.15 | 68.8 ± 27.08 |
| [MTC Cycle 5] Emotional Functional Scale (n=51,77) | 78.8 ± 23.76 | 78.7 ± 20.96 |
| [MTC Cycle 5] Cognitive Functional Scale (n=51,77) | 81.0 ± 26.04 | 84.6 ± 18.09 |
| [MTC Cycle 5] Social Functional Scale (n=51,77) | 85.3 ± 22.52 | 77.9 ± 22.85 |
| [MTC Cycle 5] Fatigue Symptom Scale (n=51,77) | 32.2 ± 23.01 | 34.5 ± 22.12 |
| [MTC Cycle 5] Nausea and Vomiting Scale (n=51,77) | 9.2 ± 18.05 | 10.0 ± 20.10 |
| [MTC Cycle 5] Pain Symptom Scale (n=51,77) | 23.5 ± 26.28 | 20.1 ± 25.27 |
| [MTC Cycle 5] Dyspnea Symptom Scale (n=51,77) | 25.5 ± 27.96 | 35.9 ± 30.95 |
| [MTC Cycle 5] Insomnia Symptom Scale( n=51,77) | 21.6 ± 28.92 | 22.1 ± 27.36 |
| MTC Cycle 5] Appetite Loss Symptom Scale (n=51,77) | 10.5 ± 19.43 | 19.9 ± 26.63 |
| [MTC Cycle 5] Constipation Symptom Scale (n=51,77) | 9.2 ± 20.09 | 17.3 ± 29.42 |
| [MTC Cycle 5] Diarrhea Symptom Scale (n=51,77) | 10.5 ± 20.54 | 2.6 ± 8.99 |
| [MTC Cycle 5] Financial Difficulties Scale n=50,77 | 16.0 ± 28.76 | 17.7 ± 23.31 |
| [MTC Cycle 7] Global Health Status Scale (n=38,64) | 61.2 ± 21.69 | 61.3 ± 19.55 |
| [MTC Cycle 7] Physical Functional Scale (n=38,64) | 75.6 ± 21.49 | 74.7 ± 19.38 |
| [MTC Cycle 7]Role Functional Scale (n=38,64) | 76.8 ± 24.97 | 70.8 ± 28.79 |
| [MTC Cycle 7]Emotional Functional Scale (n=38,64) | 81.6 ± 22.27 | 77.5 ± 18.64 |
| [MTC Cycle 7]Cognitive Functional Scale (n=38,64) | 77.2 ± 27.51 | 81.0 ± 18.98 |
| [MTC Cycle 7]Social Functional Scale (n=38,64) | 82.9 ± 24.35 | 72.1 ± 28.65 |
| [MTC Cycle 7]Fatigue Symptom Scale (n=38,64) | 32.3 ± 22.07 | 33.7 ± 24.72 |
| [MTC Cycle 7]Nausea & Vomiting Scale (n=38,64) | 8.3 ± 18.88 | 9.6 ± 16.48 |
| [MTC Cycle 7]Pain Symptom Scale (n=38,64) | 21.5 ± 23.86 | 19.8 ± 23.55 |
| [MTC Cycle 7]Dyspnea Symptom Scale (n=38,64) | 28.1 ± 26.31 | 37 ± 32.59 |
| [MTC Cycle 7]Insomnia Symptom Scale (n=38,64) | 16.7 ± 26.57 | 28.6 ± 30.21 |
| [MTC Cycle 7]Appetite Loss Scale (n=38,64) | 12.3 ± 21.11 | 21.4 ± 29.32 |
| [MTC Cycle 7]Constipation Symptom Scale (n=38,64) | 14 ± 28.61 | 17.2 ± 24.48 |
| [MTC Cycle 7]Diarrhea Symptom Scale (n=38,64) | 8.8 ± 20.04 | 8.9 ± 21.61 |
| [MTC Cycle 7]Financial Difficulties Scale n=38,64 | 14.0 ± 24.05 | 20.3 ± 27.61 |
| [MTC Cycle 9 ]Global Health Status Scale (n=33,50) | 60.6 ± 18.67 | 61.2 ± 17.71 |
| [MTC Cycle 9 ]Physical Functional Scale (n=33,50) | 80.8 ± 20.53 | 74.9 ± 19.54 |
| [MTC Cycle 9 ]Role Functional Scale (n=33,50) | 75.8 ± 24.33 | 69.7 ± 28.51 |
| [MTC Cycle 9 ]Emotional Functional Scale (n=33,50) | 82.3 ± 18.61 | 75 ± 22.46 |
| [MTC Cycle 9 ]Cognitive Functional Scale (n=33,50) | 83.3 ± 20.41 | 81.7 ± 19.99 |
| [MTC Cycle 9 ]Social Functional Scale (n=33,50) | 83.8 ± 24.47 | 71.7 ± 26.78 |
| [MTC Cycle 9 ]Fatigue Symptom Scale (n=33,50) | 28.3 ± 24.07 | 35.1 ± 25.03 |
| [MTC Cycle 9 ]Nausea & Vomiting Symptom (n=33,50) | 5.1 ± 12.14 | 12.0 ± 20.77 |
| [MTC Cycle 9 ]Pain Symptom Scale (n=33,50) | 25.8 ± 30.93 | 18.7 ± 21.47 |
| [MTC Cycle 9 ]Dyspnea Symptom Scale (n=32,50) | 25.0 ± 25.40 | 35.3 ± 27.28 |
| [MTC Cycle 9 ]Insomnia Symptom Scale (n=33,49) | 23.2 ± 26.98 | 30.6 ± 33.91 |
| [MTC Cycle 9 ]Appetite Loss Scale (n=33,50) | 10.1 ± 19.52 | 23.3 ± 29.55 |
| [MTC Cycle 9 ]Constipation Symptom Scale (n=33,50) | 13.1 ± 24.92 | 16.0 ± 25.41 |
| [MTC Cycle 9 ]Diarrhea Symptom Scale (n=33,50) | 7.1 ± 20 | 7.3 ± 18.18 |
| [MTC Cycle 9]Financial Difficulties Scale n=33,50 | 15.2 ± 23.70 | 22.0 ± 27.45 |
| [MTC Cycle 11 ] Global Health Status Scale n=25,37 | 57.7 ± 18.93 | 59.9 ± 21.41 |
| [MTC Cycle 11 ]Physical Functional Scale (n=25,37) | 79.2 ± 16.48 | 81.1 ± 17.81 |
| [MTC Cycle 11 ]Role Functional Scale (n=25,37) | 77.3 ± 18.56 | 73.9 ± 27.37 |
| [MTC Cycle 11 ]Emotional Functional Scale n=25,37 | 78.3 ± 19.09 | 80.0 ± 19.88 |
| [MTC Cycle 11 ]Cognitive Functional Scale n=25,37 | 81.3 ± 26.49 | 84.2 ± 17.10 |
| [MTC Cycle 11 ]Social Functional Scale (n=25,37) | 84.7 ± 19.20 | 77.9 ± 27.51 |
| [MTC Cycle 11 ]Fatigue Symptom Scale (n=25,37) | 32.4 ± 22.20 | 31.2 ± 20.92 |
| [MTC Cycle 11 ]Nausea & Vomiting Scale (n=25,37) | 6.7 ± 15.96 | 9.5 ± 18.23 |
| [MTC Cycle 11 ]Pain Symptom Scale (n=25,37) | 29.3 ± 28.98 | 19.8 ± 27.45 |
| [MTC Cycle 11 ]Dyspnea Symptom Scale (n=25,37) | 30.7 ± 16.44 | 28.8 ± 27.40 |
| [MTC Cycle 11 ]Insomnia Symptom Scale (n=25,37) | 20.0 ± 23.57 | 18.9 ± 26.69 |
| [MTC Cycle 11 ]Appetite Loss Scale (n=25,37) | 9.3 ± 20.46 | 18 ± 26.75 |
| MTC Cycle 11 ]Constipation Symptom Scale( n=25,37) | 6.7 ± 13.61 | 17.1 ± 24.37 |
| [MTC Cycle 11 ]Diarrhea Symptom Scale ( n=25,37) | 1.3 ± 6.67 | 7.2 ± 15.98 |
| [MTC Cycle 11]Financial Difficulties Scale n=24,37 | 15.3 ± 25.97 | 18.0 ± 26.75 |
| [EOS]Global Health Status Scale (n=123,127) | 55.1 ± 20.62 | 57.2 ± 20.01 |
| [EOS]Physical Functional Scale (n=125,127) | 70.2 ± 23.49 | 72.5 ± 22.06 |
| [EOS]Role Functional Scale (n=125,127) | 63.5 ± 32.43 | 64.3 ± 29.68 |
| [EOS]Emotional Functional Scale (n=124,127) | 74.4 ± 21.36 | 77.3 ± 20.20 |
| [EOS]Cognitive Functional Scale ( n=124,127) | 79.3 ± 24.91 | 83.5 ± 19.30 |
| [EOS]Social Functional Scale (n=124,127) | 73.3 ± 29.28 | 72.6 ± 27.90 |
| [EOS]Fatigue Symptom Scale (n=125,127) | 41.0 ± 26.42 | 37.6 ± 23.80 |
| [EOS]Nausea & Vomiting Scale (n=125,127) | 14.4 ± 23.70 | 12.3 ± 20.70 |
| [EOS]Pain Symptom Scale (n=125,127) | 30.4 ± 30.31 | 21.1 ± 25.58 |
| [EOS]Dyspnea Symptom Scale (n=124,127) | 31.5 ± 29.85 | 34.1 ± 29.83 |
| [EOS]Insomnia Symptom Scale( n=125,127) | 27.2 ± 26.57 | 22.6 ± 28.45 |
| [EOS]Appetite Loss Symptom Scale (n=125,127) | 26.9 ± 31.31 | 26.0 ± 30.26 |
| [EOS]Constipation Symptom Scale (n=125,127) | 17.6 ± 25.60 | 12.1 ± 21.28 |
| [EOS]Diarrhea Symptom Scale(n=124,127) | 9.7 ± 20.72 | 6.8 ± 15.34 |
| [EOS]Financial Difficulties Scale (n=123,126) | 16.8 ± 27.45 | 16.9 ± 27.24 |
Collected over Up to 21 months (throughout the study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| No Maintenance Treatment | — | 70/128 (54.7%) | 105/128 (82%) |
| Maintenance Treatment Arm A | — | 26/120 (21.7%) | 115/120 (95.8%) |
| Maintenance Treatment Arm B | — | 42/125 (33.6%) | 120/125 (96%) |
| Event | No Maintenance Treatment | Maintenance Treatment Arm A | Maintenance Treatment Arm B |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 9/128 | 3/120 | 2/125 |
| PneumoniaInfections and infestations | 3/128 | 1/120 | 7/125 |
| NeutropeniaBlood and lymphatic system disorders | 7/128 | 0/120 | 0/125 |
| AnaemiaBlood and lymphatic system disorders | 4/128 | 0/120 | 1/125 |
| Renal failureRenal and urinary disorders | 4/128 | 0/120 | 2/125 |
| NauseaGastrointestinal disorders | 0/128 | 2/120 | 3/125 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/128 | 1/120 | 1/125 |
| General physical health deteriorationGeneral disorders | 3/128 | 1/120 | 0/125 |
| DehydrationMetabolism and nutrition disorders | 3/128 | 0/120 | 1/125 |
| Decreased appetiteMetabolism and nutrition disorders | 3/128 | 0/120 | 0/125 |
| Event | No Maintenance Treatment | Maintenance Treatment Arm A | Maintenance Treatment Arm B |
|---|---|---|---|
| NauseaGastrointestinal disorders | 47/128 | 73/120 | 77/125 |
| HypertensionVascular disorders | 23/128 | 43/120 | 55/125 |
| AstheniaGeneral disorders | 25/128 | 42/120 | 31/125 |
| FatigueGeneral disorders | 22/128 | 22/120 | 40/125 |
| DiarrhoeaGastrointestinal disorders | 22/128 | 16/120 | 35/125 |
| ConstipationGastrointestinal disorders | 21/128 | 33/120 | 32/125 |
| VomitingGastrointestinal disorders | 21/128 | 28/120 | 33/125 |
| Decreased appetiteMetabolism and nutrition disorders | 24/128 | 23/120 | 32/125 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/128 | 27/120 | 27/125 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 17/128 | 26/120 | 24/125 |
The Intent-to-treat (ITT) population included all the participants that were randomized.
| Age, Continuous(years) | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B | Total |
|---|---|---|---|
| Mean | 59.5 ± 8.25 | 59.3 ± 8.86 | 59.4 ± 8.55 |
| Sex: Female, Male(Participants) | Bevacizumab Maintenance Trt Arm A | Bevacizumab +Pemetrexed Maintenance Trt Arm B | Total |
|---|---|---|---|
| Female | 55 | 54 | 109 |
| Male | 70 | 74 | 144 |
The record gives a start of Aug 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Pemetrexed
Carcinoma, Non-Small-Cell Lung →